Competitors
Cologuard
Abbott
Cancerguard
Operational
100

Cologuard's biggest competitor

Apathy

100

CRC is now the #X cause of cancer mortality in adults under 50

#1

100

The current Abbott CEO

Robert Ford

100

The 4 types of cancer with current screening recommendations according to our CVA

Breast, Cervical, Colorectal, Lung

100

How much is able to get reimbursed for non-covered diagnostic imaging costs after a positive Cancerguard?

$6000

200

The term for Galleri's style of MCED result

Tissue of Origin


200

The percentage of patients that are adherent on the second time and the third time

86% and 91%

200

The location of Abbott Headquarters


Chicago

200

The two Biomarker Classes used to detect cancer with Cancerguard

ctDNA Methylation and Proteins

200

The new term for "cobranding"

What is "Health System Branding"?

300

Name 2 companies that also have an MCED test available

GRAIL/Galleri, Guardant/Shield

300

The number of additional CRC cases found during colonoscopies after a positive Cologuard versus screening colonoscopy alone

5x as many

300

The year Abbott was founded (+/- 10 years)

1888

300

Cancerguard Pancreatic Detection Rate

78.4%

300

The name of the NEW portal Cancerguard can be ordered through along with our other Oncology products

Exact Sciences Provider Hub

400

The name of the new RNA-based CRC Stool-Based Screening Option

ColoSense

400

There is a X% reduced risk of CRC-related mortality with a Cologuard-first screening approach.

50%

400

The number of employees Abbott currently has (+/- 10,000)

73,000

400

Cancerguard Ovarian Cancer Detection Rate

71.4%

400

The name of the agreement/contract needed if you want to get an in-office Quest Lab added for Cancerguard screenings

TSA (Technical Service Agreement)

500

The expected average number of diagnostic procedures after a positive Cancerguard test versus a TOO test

2.6 vs 3.6

500

Cologuard every 3 years versus Colonoscopy every 10 can detect X% more precancerous lesions and X% more CRC cases

13% more precancerous lesions and 11% more CRC cases

500

Name one of the two Abbott employees that transitioned to a VP role in Cancer Diagnostics

Omar Riyal and Noelle Beckman

500

The estimated Number Needed to Treat with MCED to catch one cancer based on modeling data

33

500

Name 3 of the 6 current EMRs that offer aggregator options for Cologuard

NextGen, Athena, Veradigm, Medent, Practice Fusion, Greenway

M
e
n
u